SDX Publications

Featured SDX publications

Pharmacological Characterization of SDX-7320/Evexomostat: a Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-Tumor and Anti-Metastatic Activity (2024)

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour, Andrew J. Dannenberg, James M. Shanahan, Bradley J. Carver.

A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2 (2025)

Monica M. Mita, Alain C. Mita, Bradley J. Carver, James M. Shanahan, Benjamin A. Mayes, Pierre J. Dufour,David Browning, Alfred Anderson-Villaluz, John S. Petersen, David J. Turnquist, and Peter Cornelius

Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth (2026)

Peter Cornelius, Benjamin A. Mayes, Andrew J. Dannenberg, Pierre J. Dufour, Sara Little, Douglas V. Guzior, John S. Petersen, James M. Shanahan and Bradley J. Carver

1 Broadway Fl. 14, Cambridge, MA 02142